Published in BMC Complement Altern Med on October 29, 2007
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 35.46
Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med (1993) 28.86
Why patients use alternative medicine: results of a national study. JAMA (1998) 17.91
Use of alternative medicine by women with early-stage breast cancer. N Engl J Med (1999) 7.37
Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol (2000) 5.48
Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol (2000) 3.10
Factors associated with dietary supplement use among healthy adults of five ethnicities: the Multiethnic Cohort Study. Am J Epidemiol (2003) 2.30
Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med (1984) 2.03
Demographics, lifestyles, health characteristics, and dietary intake among dietary supplement users in Japan. Int J Epidemiol (2003) 1.85
Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med (2002) 1.85
Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". J Gen Intern Med (2001) 1.81
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr (2001) 1.55
The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer (1998) 1.27
Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care (2003) 1.22
Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care (2001) 1.19
Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J Altern Complement Med (2004) 1.18
Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother (1998) 1.16
Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc (2004) 1.12
Sex differences in motives for use of complementary and alternative medicine among cancer patients. Altern Ther Health Med (2004) 1.09
Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer (2004) 1.06
Antimutagenic effects of the mushroom Agaricus blazei Murrill extracts on V79 cells. Mutat Res (2001) 1.03
Anti-tumor polysaccharide from the mycelium of liquid-cultured Agaricus blazei mill. Biochem Mol Biol Int (1999) 1.00
Effect of hot water extract from Agaricus blazei Murill on antibody-producing cells in mice. Int Immunopharmacol (2002) 0.96
Antimutagenic effect of Agaricus blazei Murrill mushroom on the genotoxicity induced by cyclophosphamide. Mutat Res (2001) 0.92
The use of dietary supplements by veterans with cancer. J Altern Complement Med (2004) 0.92
A screening system for antioxidants using thioredoxin-deficient yeast: discovery of thermostable antioxidant activity from Agaricus blazei Murill. Appl Microbiol Biotechnol (2003) 0.91
Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biotherapy (1998) 0.87
Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med (2005) 0.84
Patient-reported measures of health: The Veterans Health Study. J Ambul Care Manage (2004) 3.30
Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol (2009) 2.40
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA (2010) 2.16
What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest (2013) 1.79
Comparing the health status of VA and non-VA ambulatory patients: the veterans' health and medical outcomes studies. J Ambul Care Manage (2004) 1.70
Racial differences in how patients perceive physician communication regarding cardiac testing. Med Care (2002) 1.58
Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account? Cancer (2008) 1.51
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Racial differences in cardiac catheterization as a function of patients' beliefs. Am J Public Health (2004) 1.47
Improving the response choices on the veterans SF-36 health survey role functioning scales: results from the Veterans Health Study. J Ambul Care Manage (2004) 1.42
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int (2014) 1.39
Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use. Cancer (2009) 1.28
Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol (2011) 1.26
Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med (2008) 1.21
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol (2013) 1.19
Applications of methodologies of the Veterans Health Study in the VA healthcare system: conclusions and summary. J Ambul Care Manage (2006) 1.18
Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer (2007) 1.17
A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNA Cell Biol (2003) 1.16
Racial differences in health-related beliefs, attitudes, and experiences of VA cardiac patients: scale development and application. Med Care (2002) 1.16
Providers' attitudes toward human papillomavirus vaccination in young men: challenges for implementation of 2011 recommendations. Am J Mens Health (2012) 1.15
Patient navigation: development of a protocol for describing what navigators do. Health Serv Res (2010) 1.12
Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control (2009) 1.12
No less a man: reconstructing identity after prostate cancer. Commun Med (2007) 0.98
Factors affecting human papillomavirus vaccine use among White, Black and Latino parents of sons. Pediatr Infect Dis J (2013) 0.97
Knowledge, attitudes, and beliefs regarding HPV vaccination: ethnic and cultural differences between African-American and Haitian immigrant women. Womens Health Issues (2012) 0.95
Utilization of medical services by Veterans Health Study (VHS) respondents. J Ambul Care Manage (2005) 0.95
What affects human papillomavirus vaccination rates? A qualitative analysis of providers' perceptions. Womens Health Issues (2012) 0.95
'The thing is not knowing': patients' perspectives on surveillance of an indeterminate pulmonary nodule. Health Expect (2012) 0.94
Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis. Clin Pediatr (Phila) (2013) 0.94
Parents' opinions of mandatory human papillomavirus vaccination: does ethnicity matter? Womens Health Issues (2010) 0.91
Why do low-income minority parents choose human papillomavirus vaccination for their daughters? J Pediatr (2010) 0.91
Assessment of long-term complications due to type 2 diabetes using patient self-report: the diabetes complications index. J Ambul Care Manage (2005) 0.91
Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol (2004) 0.90
Pulmonologists' Reported Use of Guidelines and Shared Decision-making in Evaluation of Pulmonary Nodules: A Qualitative Study. Chest (2015) 0.88
The influence of place of administration on health-related quality-of-life assessments: findings from the Veterans Health Study. J Ambul Care Manage (2005) 0.86
Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes study. Cancer (2008) 0.86
An assessment of patient navigator activities in breast cancer patient navigation programs using a nine-principle framework. Health Serv Res (2014) 0.86
Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy (2009) 0.85
Providers' perceptions of parental concerns about HPV vaccination. J Health Care Poor Underserved (2013) 0.85
Quality of life in prostate cancer. Eur J Cancer (2005) 0.81
Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep (2004) 0.80
Outcome of a randomized study of a mental health peer education and support group in the VA. Psychiatr Serv (2012) 0.79
Do better-rated navigators improve patient satisfaction with cancer-related care? J Cancer Educ (2013) 0.79
Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment? Clin Prostate Cancer (2004) 0.78
Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol (2006) 0.78
Activity of green tea polyphenol epigallocatechin-3-gallate against ovarian carcinoma cell lines. Cancer Res Treat (2004) 0.76
The value of the marginalia as an adjunct to structured questionnaires: experiences of men after prostate cancer surgery. Qual Life Res (2005) 0.76
Facilitators and barriers to the active participation of clients with serious mental illnesses in medication decision making: the perceptions of young adult clients. J Behav Health Serv Res (2015) 0.76
Preliminary validation of a patient-based self-assessment measure of severity of illness in type 2 diabetes: results from the pilot phase of the Veterans Health Study. J Ambul Care Manage (2005) 0.76
Comparison of As(2)O(3) and As(4)O(6) in the detection of SiHa cervical cancer cell growth inhibition pathway. Cancer Res Treat (2004) 0.75
Mental health and quality of life among veterans employed as peer and vocational rehabilitation specialists. Psychiatr Serv (2015) 0.75
Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer. Eval Health Prof (2005) 0.75
What Makes Patient Navigation Most Effective: Defining Useful Tasks and Networks. J Health Care Poor Underserved (2017) 0.75
Retraction: comparison of As2O3 and As4O6 in the detection of SiHa cervical cancer cell growth inhibition pathway. Cancer Res Treat (2007) 0.75